<DOC>
	<DOCNO>NCT02483871</DOCNO>
	<brief_summary>Patients treat dose escalation scheme investigate role addition statin treatment estrogen receptor positive breast cancer . Patients take oral rosuvastatin daily . The maximum number patient evaluable DLT 12 . Dosing follow : Cohort 1 - rosuvastatin 20mg , Cohort 2 - rosuvastatin 40mg . The patient total 4 blood draw 4 breast biopsy . The breast biopsy collect evaluate cholesterol metabolite tumor microenvironment characteristic include gene expression profile metabolomics . Sampling occur study entry , week 4 , week 8 , time surgery early stage patient week 16 metastatic patient . Patients begin endocrine therapy follow acquisition week 4 sample ( blood tissue biopsy ) .</brief_summary>
	<brief_title>Dose Optimization Rosuvastatin Early Stage Metastatic Estrogen Receptor Positive Breast Cancer Patients Endocrine Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Women ER+/PR+ HER2negative breast cancer initiate neoadjuvant endocrine therapy curative intent OR initiate endocrine therapy treatment metastatic breast cancer biopsy accessible primary breast tumor The patient may start FDA approved endocrine therapy ( previously treat ) week 4 trial except tamoxifen Palbociclib start week 4 , indicate Patients metastatic disease currently endocrine therapy must willing stop endocrine therapy 2 week prior start study switch new endocrine therapy study ( week 4 ) Intact breast tumor present size measure least 1cm enrollment Postmenopausal enrollment ( age ≥ 60 , age ≤ 60 amenorrhea ≥12 month absence chemotherapy , tamoxifen , ovarian suppression FSH/estradiol postmenopausal range ) ECOG ≤ 2 Can endocrine therapy willing change different endocrine therapy agent trial Must least one FDA approve endocrine therapy option patient receive prior treatment Life expectancy &gt; 12 week Laboratory criterion : normal renal function : creatinine &lt; 1.5 x upper limit normal ( ULN ) ) , liver function : bilirubin &lt; 2 x ULN , transaminases &lt; 2 x ULN blood count : WBC ≥ 2.0 , Neutrophils ≥1250 , platelets ≥50,000 , Hemoglobin ≥ 8 . Age &gt; 18 year Patients must ability give informed consent . Patients must sign informed consent form prior enrollment study . Statin use last 6 month Patient treat FDA approve endocrine therapy treat FDA approve endocrine therapy except tamoxifen ( tamoxifen exclude trial ) Active liver disease elevate transaminase &gt; 2x ULN Known hypersensitivity rosuvastatin Any history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix ) unless patient remission cancer therapy least 3 year . Patients significant psychiatric illness medical illness would preclude ability comply protocol . Patients currently take medication know rosuvastatin interaction include cyclosporine , gemfibrozil , lopinavir/ritonavir , atazanavir/ritonavir , coumarin anticoagulant , colchicine , fenofibrates , niacin .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Estrogen Receptor Positive</keyword>
</DOC>